文献速递神经肿瘤

PET RANO 1.0与RANO 2.0标准在IDH野生型胶质母细胞瘤试验入组中的比较

PET RANO 1.0 vs. RANO 2.0 criteria for trial eligibility in IDH-wildtype glioblastoma: a retrospective, comparative study.
PubMed 文献 · Neuro Oncol · 2026-08-14

该回顾性单中心研究纳入322例IDH野生型胶质母细胞瘤患者,在标准化放疗后(T0)或首次进展时(T1)同时行[¹⁸F]FET PET和MRI,比较PET RANO 1.0与RANO 2.0标准检出的可测量病灶频率。结果显示PET在T0和T1均显著检出更多可测量病灶(91.1% vs 50.9%;95.7% vs 65.2%,p=0.001),提示PET可能拓宽临床试验入组。

要点

  • PET RANO 1.0较RANO 2.0显著提高可测量病灶检出率。
  • 放疗后T0时PET检出91.1% vs MRI 50.9%可测量病灶。
  • 首次进展T1时PET检出95.7% vs MRI 65.2%可测量病灶。

核心结论

  • PET RANO 1.0检出的可测量病灶患者比例显著高于RANO 2.0。
  • 结果支持前瞻性验证PET为基础的可测量病灶作为IDH野生型胶质母细胞瘤试验入组标准。

研究设计与样本

  • 回顾性单中心研究,纳入322例IDH野生型胶质母细胞瘤患者。
  • T0为标准化一线放疗后(按RANO 2.0定义),共112例,中位年龄59岁(IQR 54-69)。
  • T1为首次进展时,共210例,中位年龄59岁(IQR 53-67)。
  • 两名独立评估者分别按PET RANO 1.0和RANO 2.0标准评估可测量病灶。

主要发现

  • MRI可测量病灶:T0为57/112例(50.9%),T1为137/210例(65.2%)。
  • MRI中位横截面直径乘积之和:T0为143mm²,T1为187mm²。
  • PET可测量病灶:T0为102/112例(91.1%),T1为201/210例(95.7%)。
  • PET中位体积:T0为9.86cm³,T1为14.3cm³。
  • PET与MRI检出可测量病灶的差异具有统计学意义(p=0.001)。

关键数值与推荐

  • PET RANO 1.0基于氨基酸PET标准化评估可测量病灶。
  • RANO 2.0基于MRI评估可测量病灶。
  • T0定义为标准化一线放疗后时间点,T1定义为首次进展时间点。

临床怎么用

  • 在临床试验入组筛查中,可考虑氨基酸PET补充MRI评估可测量病灶。
  • PET有助于检出MRI上无强化的代谢活跃肿瘤,可能扩大试验入组人群。

局限性

  • 回顾性单中心设计。
  • 结果需前瞻性验证后方可作为试验入组标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In glioblastoma studies, the presence of measurable disease is often required for trial eligibility. While response assessment according to RANO 2.0 relies on MRI, the recently introduced PET RANO 1.0 criteria allow standardized evaluation based on amino acid PET. This study compares the frequency of measurable disease according to PET RANO 1.0 vs. RANO 2.0 criteria at key enrollment timepoints of clinical trials. METHODS: In this retrospective, single-center study, we included patients with IDH-wildtype glioblastoma who underwent both [¹⁸F]FET PET and MRI, after standard first-line radiotherapy (time-point T0) (defined per RANO 2.0) or at first progression (time-point T1). Two independent raters evaluated measurable disease using PET RANO 1.0 and RANO 2.0 criteria. Further, tumor size, target lesions and tracer uptake metrics were analyzed. RESULTS: In total 322 patients were included, 112 at T0 (median age: 59 years, IQR 54-69), and 210 at T1 (median age: 59, IQR 53-67). On MRI, measurable disease was identified in 57/112 patients (50.9%) at T0 and in 137/210 patients (65.2%) at T1 (median sum of products of cross-sectional diameters: 143mm2; 187mm2). On PET, significantly more cases with measurable disease were detected: 102/112 patients, (91.1%) at T0 and 201/210 patients (95.7%) at T1 (median volumes: 9.86cm³; 14.3cm³) (p = 0.001). CONCLUSION: PET RANO 1.0 detects a substantially larger subset of patients with measurable disease compared to RANO 2.0. These findings warrant prospective validation of PET-based measurable disease as an inclusion criterion for clinical trials in IDH-wildtype glioblastoma, with the potential to broaden trial eligibility. This study compared two imaging methods for assessing glioblastoma, the most frequent and aggressive brain tumor, after radiotherapy and at first disease progression. The standard MRI-based criteria were compared with PET criteria, which uses amino acid PET imaging to detect metabolically active tumor cells. The researchers found that PET identified measurable tumor burden significantly more often than MRI at these key time points, which are commonly used for clinical trial enrollment. These results suggest that PET can provide important additional information beyond MRI, particularly for detecting tumor that does not enhance on MRI, potentially increasing trial eligibility.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Schmidbauer KJ, von Polenz I, Reis J, et al. PET RANO 1.0 vs. RANO 2.0 criteria for trial eligibility in IDH-wildtype glioblastoma: a retrospective, comparative study. Neuro Oncol. 2026. PMID: 42599218. doi:10.1093/neuonc/noag182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。